1. Home
  2. EZGO vs TVRD Comparison

EZGO vs TVRD Comparison

Compare EZGO & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo EZGO Technologies Ltd.

EZGO

EZGO Technologies Ltd.

N/A

Current Price

$0.90

Market Cap

28.4M

ML Signal

N/A

Logo Tvardi Therapeutics Inc.

TVRD

Tvardi Therapeutics Inc.

HOLD

Current Price

$2.02

Market Cap

27.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EZGO
TVRD
Founded
2014
2017
Country
China
United States
Employees
N/A
12
Industry
Motor Vehicles
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
28.4M
27.5M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
EZGO
TVRD
Price
$0.90
$2.02
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$29.50
AVG Volume (30 Days)
98.3K
6.5M
Earning Date
07-01-2025
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.01
$1.50
52 Week High
$3.30
$43.65

Technical Indicators

Market Signals
Indicator
EZGO
TVRD
Relative Strength Index (RSI) 36.58 38.25
Support Level $0.88 $1.50
Resistance Level $1.34 $4.32
Average True Range (ATR) 0.10 0.30
MACD -0.02 -0.10
Stochastic Oscillator 5.66 2.39

Price Performance

Historical Comparison
EZGO
TVRD

About EZGO EZGO Technologies Ltd.

EZGO Technologies Ltd is engaged in the sale of e-bicycles and battery and e-bicycle rentals, complemented by the sale of battery packs, battery cell trading and charging pile business. Its product categories include e-bicycle, Intelligent unmanned patrol car, e-motorcycle and e-moped and urban style e-tricycle. Its segments include the Battery cells and packs, electronic control system and intelligent robot segment. and the E-bicycle sales segment. The company generates maximum revenue from the Battery cells and packs segment.

About TVRD Tvardi Therapeutics Inc.

Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.

Share on Social Networks: